Core Viewpoint - Climb Bio, Inc. is actively engaging with investors through participation in multiple upcoming healthcare conferences, showcasing its commitment to transparency and investor relations [1][2][3]. Group 1: Upcoming Conferences - Climb Bio will participate in the Cantor Global Healthcare Conference on September 5, 2025, featuring a fireside chat and one-on-one investor meetings [2]. - The company will also attend the Baird Global Healthcare Conference on September 9, 2025, with a similar format of fireside chat and one-on-one meetings [2]. - Additionally, Climb Bio is scheduled for the Morgan Stanley Annual Global Healthcare Conference on September 10, 2025, which will consist of one-on-one meetings only [2]. Group 2: Virtual Forum - Climb Bio will take part in the Stifel Virtual Immunology and Inflammation Forum on September 10, 2025, offering a presentation and one-on-one investor meetings [3]. - Live webcasts of these events will be accessible on the Climb Bio website, with replays available approximately two hours after each event and archived for at least 30 days [3]. Group 3: Company Overview - Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases [4]. - The company's pipeline includes budoprutug, an anti-CD19 monoclonal antibody aimed at treating a range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy [4].
Climb Bio to Present at Upcoming September 2025 Investor Conferences